New treatment before surgery for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving serplulimab (an immune medicine) plus CAPEOX chemotherapy and celecoxib before surgery can shrink locally advanced rectal cancer and improve outcomes. It may help by increasing immune attack on the tumor while chemotherapy helps reduce the cancer before the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old, and you can sign consent
- Your rectal cancer is adenocarcinoma (documented by biopsy/pathology), and you haven’t had chemotherapy for rectal cancer before
- Your tumor is within 10 cm of the anus, and MRI shows specific features (including a negative MRF) and the cancer stage fits cT2-4 and N0-2 without distant spread
- Your health status is good enough (ECOG 0–1) and the trial team can test tumor tissue for MSI/MMR
- You can participate based on virus/liver blood tests (for example, no hepatitis B or—if present—well-controlled levels; and no combined hepatitis B and C)
- You have no major “reasons to stop,” like prior pelvic radiation, inflammatory bowel disease, active HIV/AIDS, recent major surgery, or prior immune checkpoint antibody treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
This trial tests a combination of radiation therapy, chemotherapy, and immunotherapy given before surgery for rectal cancer that has high-risk features. The goal is to shrink the tumor and improve outcomes for patients with this aggressive form of cancer.
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
This trial tests if adding immunotherapy and an anti-angiogenesis drug to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer that has not spread. You may benefit if your tumor is in the lower part of the rectum and you haven't had prior cancer treatment.
Hear when a new pMMR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.